Using Tranexamic Acid to Treat Skin Pigmentation Disorders
The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans
This study is testing if tranexamic acid can help people with skin pigmentation disorders like lichen planus pigmentosus and erythema dyschromicum perstans feel better and improve their skin color.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 5 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Henry Ford Health System Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Trial ID | NCT04233749 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the efficacy of tranexamic acid in treating lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP), two challenging pigmentary disorders. The study aims to determine if tranexamic acid, known for its ability to reduce pigmentation in melasma, can similarly benefit patients with LPP and EDP. Participants will receive tranexamic acid tablets after a washout period from other treatments. The trial will assess changes in pigmentation and overall skin condition in affected individuals.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with LPP, EDP, or ashy dermatosis.
Not a fit: Patients with a history of clotting disorders, active malignancies, or severe renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients suffering from LPP and EDP, improving their skin appearance and quality of life.
How similar studies have performed: While tranexamic acid has shown promise in treating melasma, its application for LPP and EDP is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject age 18 and older * Subject with a diagnosis of LPP, EDP, or AD * Subject able to understand requirements of the study and risks involved * Subject able to sign a consent form * Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment Exclusion Criteria: * Personal history of clotting disorder or thromboembolic disease (deep vein thrombosis (DVT), stroke, etc) * Active malignancy, excluding non-melanoma skin cancer * Moderate to severe renal impairment * History of migraine with aura * Current anticoagulant therapy * Current use of hormonal contraception or hormone replacement therapy in the last 30 days * A woman who is lactating, pregnant, or planning to become pregnant
Where this trial is running
Detroit, Michigan
- New Center One — Detroit, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Henry W Lim, MD — Henry Ford HS
- Study coordinator: Angela Parks-Miller, RN
- Email: amiller5@hfhs.org
- Phone: 1-313-916-0426
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.